Burzynski: Cancer Is Serious Business – Part II – Documentary
This story is a follow-up to the first documentary about Burzynski, a doctor and biochemist, who in late ’60s discovered a new group of peptides in our bodies. After escaping from communist Poland to live in Houston in the 70’s, Stanislaw Burzynski persisted in the research of his peptide finding and realized that people with cancer seemed to have low levels or lacked altogether these peptides.
He speculated that restoring these peptide levels could potentially be helpful in controlling cancer. Burzynski discovered how to synthesize these peptides, patented them, and named them Antineoplastons. He then lunched a publicly traded corporation, and entered the United States Food and Drug Administration (FDA) clinical trial process to get Antineoplastons approved for market using his own newly formed pharmaceutical company – Burzynski Research Institute, Inc. And that’s when… all hell broke loose.
American Government abandoned their primary attempt to take over these medicines after they submitted 11 patents of an already existing Antineoplastons by recruiting and conspiring with one of Burzynski’s scientists. As of now, Antineoplastons have successfully completed a series of FDA authorized Phase 2 clinical trials.
Dr. Stanislaw Burzynski is, at the moment, the first and only scientist in United States history to start the federal drug authorization process for a medical cancer therapy without any financial backing from the American Government, the Pharmaceutical industry or the Cancer Establishment. As of the year 2013, only 10% of the patients that seek Burzynski’s therapy are allowed to receive Antineoplastons due to strictly imposed federal government sanctions that limit who is, and who is not, allowed to receive them.
The patients that wish to receive Antineoplastons are required to go through a rigorous review process by America’s Food and Drug Administration which generally requires proof that chemotherapy and radiation have first failed the patient, before being allowed access to Antineoplastons. Even if the FDA’s prerequisite is fulfilled, the FDA holds full dictatorial rights to refuse patients’access to Antineoplastons if they chose.